Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen:
doi:10.22028/D291-47588 | Titel: | Effects of Resistant Starch on Symptoms, Fecal Markers, and Gut Microbiota in Parkinson's Disease - The RESISTA-PD Trial |
| VerfasserIn: | Becker, Anouck Schmartz, Georges Pierre Gröger, Laura Grammes, Nadja Galata, Valentina Philippeit, Hannah Weiland, Jacqueline Ludwig, Nicole Meese, Eckart Tierling, Sascha Walter, Jörn Schwiertz, Andreas Spiegel, Jörg Wagenpfeil, Gudrun Faßbender, Klaus Keller, Andreas Unger, Marcus M. |
| Sprache: | Englisch |
| Titel: | Genomics Proteomics Bioinformatics |
| Bandnummer: | 20 (2022) |
| Heft: | 2 |
| Seiten: | 274-287 |
| Verlag/Plattform: | Elsevier |
| Erscheinungsjahr: | 2021 |
| Freie Schlagwörter: | Parkinson’s disease Short-chain fatty acid Microbiota Metagenomics Intestinal inflammation |
| DDC-Sachgruppe: | 500 Naturwissenschaften 610 Medizin, Gesundheit |
| Dokumenttyp: | Journalartikel / Zeitschriftenartikel |
| Abstract: | The composition of the gut microbiota is linked to multiple diseases, including Parkin son’s disease (PD). Abundance of bacteria producing short-chain fatty acids (SCFAs) and fecal SCFA concentrations are reduced in PD. SCFAs exert various beneficial functions in humans. In the interventional, monocentric, open-label clinical trial ‘‘Effects of Resistant Starch on Bowel Habits, Short Chain Fatty Acids and Gut Microbiota in Parkinson’s Disease” (RESISTA-PD; ID: NCT02784145), we aimed at altering fecal SCFAs by an 8-week prebiotic intervention with resistant starch (RS). We enrolled 87 subjects in three study-arms: 32 PD patients received RS (PD +RS),30control subjects received RS, and 25 PD patients received solely dietary instructions. We performed paired-end 100 bp length metagenomic sequencing of fecal samples using the BGISEQ platform at an average of 9.9 GB. RS was well-tolerated. In the PD + RS group, fecal butyrate concentrations increased significantly, and fecal calprotectin concentrations dropped significantly after 8 weeks of RS intervention. Clinically, we observed a reduction in non-motor symptomloadinthePD+RSgroup.Thereference-basedanalysisofmetagenomeshighlightedstable alpha-diversity and beta-diversity across the three groups, including bacteria producing SCFAs. Reference-free analysis suggested punctual, yet pronounced differences in the metagenomic signature in the PD + RS group. RESISTA-PD highlights that a prebiotic treatment with RS is safe and well-tolerated in PD. The stable alpha-diversity and beta-diversity alongside altered fecal butyrate and calprotectin concentrations call for long-term studies, also investigating whether RS is able to modify the clinical course of PD. |
| DOI der Erstveröffentlichung: | 10.1016/j.gpb.2021.08.009 |
| URL der Erstveröffentlichung: | https://doi.org/10.1016/j.gpb.2021.08.009 |
| Link zu diesem Datensatz: | urn:nbn:de:bsz:291--ds-475882 hdl:20.500.11880/41610 http://dx.doi.org/10.22028/D291-47588 |
| ISSN: | 2210-3244 1672-0229 |
| Datum des Eintrags: | 28-Apr-2026 |
| Fakultät: | M - Medizinische Fakultät NT - Naturwissenschaftlich- Technische Fakultät |
| Fachrichtung: | M - Humangenetik M - Medizinische Biometrie, Epidemiologie und medizinische Informatik M - Neurologie und Psychiatrie NT - Biowissenschaften |
| Professur: | M - Prof. Dr. Klaus Faßbender M - Univ.-Prof. Dr. Andreas Keller M - Prof. Dr. Eckart Meese NT - Prof. Dr. Jörn Walter |
| Sammlung: | SciDok - Der Wissenschaftsserver der Universität des Saarlandes |
Dateien zu diesem Datensatz:
| Datei | Beschreibung | Größe | Format | |
|---|---|---|---|---|
| gpb_20_2_274.pdf | 2,45 MB | Adobe PDF | Öffnen/Anzeigen |
Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons

